论文部分内容阅读
目的:检测肝癌患者血浆中P53基因突变的机率,研究与疾病发生、发展的相关性并探讨其意义。方法:实验采用聚合酶联链式反应(PCR)扩增P53基因外显子5~8,对其突变进行分析。结合临床患者有无肝组织以外转移来对比差异性。结果:33例肝癌患者中,有17例结果显示血浆循环核酸P53基因突变;有转移病灶组18例的突变率高于无转移病灶组15例。结论:血浆P53基因突变与肝癌的发生可能有相关性,与疾病的轻重、病灶转移有某种内在联系,突变机率在临床鉴别诊断和治疗预后中有参考价值。
Objective: To detect the probability of P53 gene mutation in plasma of patients with hepatocellular carcinoma (HCC) and to study the correlation with the occurrence and development of P53 gene and its significance. Methods: The exon 5 ~ 8 of P53 gene was amplified by polymerase chain reaction (PCR), and its mutation was analyzed. With clinical patients with or without liver metastasis to compare the difference. Results: Of the 33 HCC patients, 17 showed a mutation in the plasma circulating nucleic acid P53 gene. The mutation rate in 18 patients with metastasis was higher than that in 15 patients without metastasis. Conclusion: The mutation of plasma P53 may be related to the occurrence of hepatocellular carcinoma. There is a certain relationship between the P53 gene mutation and the severity of the disease and the metastasis of the tumor. The mutation probability has reference value in the differential diagnosis and prognosis of the disease.